文献速递前列腺癌

根治性前列腺切除术后生化失败挽救性放疗联合短期与长期雄激素剥夺治疗的随机试验:URONCOR 06-24

A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.
PubMed 文献 · BJU Int · 2024-07-23

URONCOR 06-24是一项前瞻性、多中心、随机、开放标签、III期临床试验,旨在比较短期(6个月)与长期(24个月)雄激素剥夺治疗(ADT)联合挽救性放疗(SRT)对根治性前列腺切除术后生化复发(BCR)中高危前列腺癌患者远处无转移生存(MFS)的影响。计划入组534例患者,1:1随机接受6个月或24个月黄体生成素释放激素类似物联合SRT,按风险组和病理淋巴结状态分层。主要终点为5年MFS率。

要点

  • URONCOR 06-24试验比较SRT联合6个月与24个月ADT对中高危BCR患者5年MFS的影响。
  • 计划入组534例,1:1随机,按风险组和病理淋巴结状态分层。
  • 主要终点为5年MFS率,次要终点包括生化复发间期、盆腔无进展生存等。

核心结论

  • 该试验旨在确定短期(6个月)与长期(24个月)ADT联合SRT对根治性前列腺切除术后生化复发中高危前列腺癌患者远处无转移生存的影响。

研究设计与样本

  • URONCOR 06-24(NCT05781217)是一项前瞻性、多中心、随机、开放标签、III期临床试验,计划入组534例患者,1:1随机接受6个月或24个月ADT联合SRT,按风险组和病理淋巴结状态分层。

关键数值与推荐

  • ADT方案为黄体生成素释放激素类似物,短期为6个月,长期为24个月。
  • 主要终点为5年远处无转移生存率。
  • 次要终点包括生化复发间期、盆腔无进展生存、开始全身治疗时间、去势抵抗时间、癌症特异性生存、总生存、急性和晚期毒性以及生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salvage radiotherapy (SRT) and androgen-deprivation therapy (ADT) are widely used in routine clinical practice to treat patients with prostate cancer who develop biochemical recurrence (BCR) after radical prostatectomy (RP). However, there is no standard-of-care consensus on optimal duration ADT. Investigators propose three distinct risk groups in patients with prostate cancer treated with SRT in order to better define the indications and duration of ADT combined with SRT. STUDY DESIGN: The URONCOR 06-24 trial (ClinicalTrials.gov identifier NCT05781217) is a prospective, multicentre, randomised, open-label, phase III, clinical trial. The aim of the trial is to determine the impact of short-term (6 months) vs long-term (24 months) ADT in combination with SRT on distant metastasis-free survival (MFS) in patients with prostate cancer with BCR after RP (intermediate and high risk). ENDPOINTS: The primary endpoint is 5-year MFS rates in patients with prostate cancer treated with long- vs short-term ADT in combination with SRT. Secondary objectives are biochemical-relapse free interval, pelvic progression-free survival, time to start of systemic treatment, time to castration resistance, cancer-specific survival, overall survival, acute and late toxicity, and quality of life. METHODS AND ANALYSIS: Total of 534 patients will be randomised 1:1 to ADT 6 months or ADT 24 months with a luteinizing hormone-releasing hormone analogue in combination with SRT, stratified by risk group and pathological lymph node status. ETHICS AND DISSEMINATION: The study is conducted under the guiding principles of the World Medical Association Declaration of Helsinki. The results will be disseminated at research conferences and in peer-reviewed journals. TRIAL REGISTRATION NUMBER: EudraCT number 2021-006975-41.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. González-San Segundo C, López Campos F, Gómez Iturriaga A, et al. A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24. BJU Int. 2024. PMID: 39041411. doi:10.1111/bju.16484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。